Prostate SABR With Intra-Prostatic SABR Boost
Launched by KING SAUD UNIVERSITY · Dec 26, 2019
Trial Information
Current as of August 19, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a treatment called Stereotactic Ablative Radiation (SABR) for men with high-risk prostate cancer. In this study, patients will receive a specific dose of radiation directed at their prostate, and a higher dose will be given to any cancer nodules that are found using MRI. This treatment aims to target the cancer more effectively while also treating nearby areas like the pelvic lymph nodes. The trial is currently looking for participants aged between 65 and 74 who have been diagnosed with high-risk prostate cancer, which includes certain features indicating a more aggressive disease.
To be eligible for the trial, participants must have a confirmed diagnosis of prostate adenocarcinoma and meet specific criteria, such as having certain test results or cancer characteristics. Participants can expect to receive five weekly radiation treatments, with the hope of improving their cancer outcomes. It's important to note that individuals with previous radiation treatment in the pelvic area or certain health conditions may not qualify for this study. If a patient is interested, they will need to provide informed consent to participate.
Gender
MALE
Eligibility criteria
- Inclusion Criteria:
- • Histologically confirmed prostate adenocarcinoma
- • High-risk prostate cancer, defined as at least one of: T3, Gleason 8-10, OR PSA \> 20 ng/mL
- • Willing to give informed consent to participate in this clinical trial
- Exclusion Criteria:
- • Prior pelvic radiotherapy
- • Contraindication to radical prostate radiotherapy e.g. connective tissue disease or inflammatory bowel disease
- • Contraindication to prostate MRI
- • No evidence of castrate resistance (defined as PSA \< 3 ng/ml while testosterone is \< 0.7nmol/l. Patients could have been on combined androgen blockade but are excluded if this was started due to PSA progression.
- • Definitive extrapelvic nodal or distant metastatic disease on staging investigations.
About King Saud University
King Saud University (KSU), established in 1957, is a leading higher education institution in Saudi Arabia, renowned for its commitment to advancing research and innovation in various fields, including health sciences. With a robust infrastructure and a diverse pool of expert faculty, KSU actively engages in clinical trials aimed at improving healthcare outcomes and addressing pressing medical challenges. The university prioritizes ethical research practices and collaboration with local and international partners to contribute to the global body of medical knowledge, ultimately enhancing patient care and public health in the region and beyond.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Riyadh, , Saudi Arabia
Patients applied
Trial Officials
Yasir Alayed, MD
Principal Investigator
King Saud Medical City
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials